April 2009 Volume 27 Number 4, pp 297 - 396
Visit Nature biotechnology online to browse the journal.
Now available at http://links.ealert.nature.com/ctt?kn=58&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access to Nature biotechnology online. To purchase a subscription, please visit:
http://links.ealert.nature.com/ctt?kn=32&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=40&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
Bioentrepreneur: an online resource for budding business in the life sciences.
http://links.ealert.nature.com/ctt?kn=4&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
qPCR - Ready, Set, Done!
Easily and quickly quantify genes in cellular pathways and gene families.
RealTime ready Focus Panels are pre-plated with gene-specific primers, probes, controls and reference genes.
Just add master mix and sample cDNA. More RealTime ready information is available here.
=====================================================================
=========================== ADVERTISEMENT ===========================
Immediate access to high-throughput sequencing - When it comes to
sequencing it's time to accelerate your thinking. Candidate gene
resequencing, whole genome sequencing, digital gene expression,
mRNA or ChIP sequencing, we have the experience and capacity to
meet your needs NOW! Also inquire about our novel genome enrichment
technologies. 866-293-6094
http://links.ealert.nature.com/ctt?kn=50&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
Harvard Business School Executive Education
http://links.ealert.nature.com/ctt?kn=56&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
Tomorrow's leaders are innovating through today's recession.
Are you one of them?
Clayton Christensen contends that breakthrough innovations often come
when tension is greatest and resources are most limited. We invite you
to read his interview (http://links.ealert.nature.com/ctt?kn=114&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
with The Wall Street Journal and learn more about HBS's science-business programs.
http://links.ealert.nature.com/ctt?kn=124&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
=====================================================================
=====================================================================
BIOPARTNERING
Visit our Biopartnering site to view Company Profiles and Partnership Opportunities:
=====================================================================
=========================== ADVERTISEMENT ===========================
FREE ARTICLE
Programming antibodies to treat cancer and autoimmune diseases.
http://links.ealert.nature.com/ctt?kn=98&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
Scripps researchers have devised a means of inducing antibodies by vaccine and then programming them with a target-specific molecule in vivo to treat mouse models of cancer. Programmed antibodies could also be used to treat autoimmune diseases, although it is not yet clear that they could treat infectious diseases. How does this approach change the landscape for conventional vaccine or infused antibody therapies?
Find out more by reading the first in-depth analysis of the scientific and commercial potential of the work in SciBX: Science-Business eXchange.
http://links.ealert.nature.com/ctt?kn=108&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
=====================================================================
----------------------
EDITORIAL
----------------------
Making a difference p297
If there is one thing that the new team at the US Food and Drug Administration should immediately implement, it is a comprehensive, open database of drug-related adverse events.
doi:10.1038/nbt0409-297
http://links.ealert.nature.com/ctt?kn=61&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
----------------------
NEWS
----------------------
Pharma swept up in biogenerics gold rush pp299 - 301
Mark Ratner
doi:10.1038/nbt0409-299
http://links.ealert.nature.com/ctt?kn=92&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
One-off therapy for HIV p300
Joe Alper
doi:10.1038/nbt0409-300
http://links.ealert.nature.com/ctt?kn=140&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
First US approval for a transgenic animal drug pp302 - 304
Jim Kling
doi:10.1038/nbt0409-302
http://links.ealert.nature.com/ctt?kn=22&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
RIP Raptiva? p303
Laura DeFrancesco
doi:10.1038/nbt0409-303
http://links.ealert.nature.com/ctt?kn=81&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
EU impasse over GM deepens p304
Anna Meldolesi
doi:10.1038/nbt0409-304a
http://links.ealert.nature.com/ctt?kn=130&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
Cellulosic ethanol stimulus p304
Emily Waltz
doi:10.1038/nbt0409-304b
http://links.ealert.nature.com/ctt?kn=134&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
Competition intensifies around hepatitis C pp305 - 306
Emma Dorey
doi:10.1038/nbt0409-305a
http://links.ealert.nature.com/ctt?kn=103&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
Indian biotechs partner with government p305
K S Jayaraman
doi:10.1038/nbt0409-305b
http://links.ealert.nature.com/ctt?kn=118&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
Malaysia seeks biotech partners p305
Susan Aldridge
doi:10.1038/nbt0409-305c
http://links.ealert.nature.com/ctt?kn=116&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
Genentech's Cabilly victory p307
Emily Waltz
doi:10.1038/nbt0409-307
http://links.ealert.nature.com/ctt?kn=132&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
PROFILE
Corey Goodman p308
Meet the man behind Pfizer's recent decision to bet its entire R&D effort on the biotech model.
Jim Kling
doi:10.1038/nbt0409-308
http://links.ealert.nature.com/ctt?kn=47&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
NEWS FEATURE
New relief for gout pp309 - 311
A gout drug has been approved by the FDA, the first in 40 years, with three more in the wings. What accounts for this sudden slew of gout therapies? Jill U. Adams investigates.
Jill U Adams
doi:10.1038/nbt0409-309
http://links.ealert.nature.com/ctt?kn=34&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
----------------------
BIOENTREPRENEUR
----------------------
BUILDING A BUSINESS
Lab relocation roulette: it's your move
Whether your lab lease has expired or it's simply time for more space, moving entails more than just boxes and duct tape.
Richard Sayre
doi:10.1038/bioe.2009.2
http://links.ealert.nature.com/ctt?kn=90&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
----------------------
OPINION AND COMMENT
----------------------
CORRESPONDENCE
Incentives for Brazilian health biotech pp317 - 318
Luiz A B Castro and Allan Kardec Barros
doi:10.1038/nbt0409-317
http://links.ealert.nature.com/ctt?kn=110&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
German GM research-a personal account pp318 - 319
Stefan Rauschen
doi:10.1038/nbt0409-318
http://links.ealert.nature.com/ctt?kn=101&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
A kernel for the Tropical Disease Initiative pp320 - 321
Leticia Orti et al.
doi:10.1038/nbt0409-320
http://links.ealert.nature.com/ctt?kn=80&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
Of Newtons and heretics pp321 - 322
Agomoni Ganguli-Mitra et al.
doi:10.1038/nbt0409-321
http://links.ealert.nature.com/ctt?kn=88&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
COMMENTARY
Leveraging biotech's drug discovery expertise for neglected diseases pp323 - 329
More needs to be done to tap the potential of drug discovery programs in mid-tier biotech companies for innovative treatments against neglected diseases.
Joanna E Lowell and Christopher D Earl
doi:10.1038/nbt0409-323
http://links.ealert.nature.com/ctt?kn=136&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
----------------------
BOOK REVIEW
----------------------
Drowning in good ideas p330
Bruce Berman reviews The Gridlock Economy: How Too Much Ownership Wrecks Markets, Stops Innovation and Costs Lives by Michael Heller
doi:10.1038/nbt0409-330
http://links.ealert.nature.com/ctt?kn=138&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
----------------------
FEATURES
----------------------
Development trends for therapeutic antibody fragments pp331 - 337
Although fewer antibody fragments have entered the clinic than full-length monoclonal antibodies, proof-of-concept studies for these therapeutics remain the main hurdle.
Aaron L Nelson and Janice M Reichert
doi:10.1038/nbt0409-331
http://links.ealert.nature.com/ctt?kn=20&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
PATENTS
New guidance on the patentability of embryonic stem cell patents in Europe pp338 - 339
The European Patent Office rules in the latest installment of the prosecution of the WARF patents.
Robert Fitt
doi:10.1038/nbt0409-338
http://links.ealert.nature.com/ctt?kn=39&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
Recent patent applications in high-throughput screening p340
doi:10.1038/nbt0409-340
http://links.ealert.nature.com/ctt?kn=51&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Locking in on the human methylome pp341 - 342
Two groups have combined padlock probes and massively parallel sequencing to characterize cytosine methylation in targeted regions of the human genome.
Benjamin P Berman, Daniel J Weisenberger and Peter W Laird
doi:10.1038/nbt0409-341
http://links.ealert.nature.com/ctt?kn=18&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
A whale of a library pp342 - 344
The MoBY-ORF collection of barcoded yeast genes provides mechanistic insights into antiproliferative compounds.
Deming Xu and Terry Roemer
doi:10.1038/nbt0409-342
http://links.ealert.nature.com/ctt?kn=83&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
Getting to the core of the gut microbiome pp344 - 346
Metagenomic analysis of gastrointestinal bacteria sheds light on obesity.
Matthias H Tschop, Philip Hugenholtz and Christopher L Karp
doi:10.1038/nbt0409-344
http://links.ealert.nature.com/ctt?kn=87&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
Missing lincs in the transcriptome pp346 - 347
Are long, intervening noncoding (linc) RNAs a new class of functional transcripts?
Thomas Gingeras
doi:10.1038/nbt0409-346
http://links.ealert.nature.com/ctt?kn=28&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
----------------------
RESEARCH HIGHLIGHTS
----------------------
Research highlights p348
doi:10.1038/nbt0409-348
http://links.ealert.nature.com/ctt?kn=7&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
----------------------
COMPUTATIONAL BIOLOGY
----------------------
PRIMER
SNP imputation in association studies pp349 - 351
Only a subset of single-nucleotide polymorphisms (SNPs) can be genotyped in genome-wide association studies. Imputation methods can infer the alleles of 'hidden' variants and use those inferences to test the hidden variants for association.
Eran Halperin and Dietrich A Stephan
doi:10.1038/nbt0409-349
http://links.ealert.nature.com/ctt?kn=54&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
----------------------
RESEARCH
----------------------
ARTICLES
Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming pp353 - 360
Jie Deng et al.
doi:10.1038/nbt.1530
Abstract: http://links.ealert.nature.com/ctt?kn=78&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=10&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells pp361 - 368
Madeleine P Ball et al.
doi:10.1038/nbt.1533
Abstract: http://links.ealert.nature.com/ctt?kn=43&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=70&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
A molecular barcoded yeast ORF library enables mode-of-action analysis of bioactive compounds pp369 - 377
Cheuk Hei Ho et al.
doi:10.1038/nbt.1534
Abstract: http://links.ealert.nature.com/ctt?kn=73&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=55&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins pp378 - 386
Bernd Wollscheid et al.
doi:10.1038/nbt.1532
Abstract: http://links.ealert.nature.com/ctt?kn=66&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=99&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
Identification of selective inhibitors of uncharacterized enzymes by high-throughput screening with fluorescent activity-based probes pp387 - 394
Daniel A Bachovchin, Steven J Brown, Hugh Rosen and Benjamin F Cravatt
doi:10.1038/nbt.1531
Abstract: http://links.ealert.nature.com/ctt?kn=113&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=95&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
----------------------
NATUREJOBS
----------------------
CAREERS AND RECRUITMENT
Biotech hirings and firings p395
Michael Francisco
doi:10.1038/nbt0409-395
http://links.ealert.nature.com/ctt?kn=133&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
PEOPLE
People p396
doi:10.1038/nbt0409-396
http://links.ealert.nature.com/ctt?kn=106&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Natureevents Directory 2009
The FREE digital edition of the Natureevents Directory 2009 is now available!
Visit http://links.ealert.nature.com/ctt?kn=123&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0 to download the complete resource for global scientific events and start planning your conference attendance for the year ahead.
To advertise events please contact natureevents@nature.com
=====================================================================
You have been sent this Table of Contents Alert because you have opted in to
receive it. You can change or discontinue your e-mail alerts at any time,
by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=19&m=32253691&r=MTc3MTg2NzE2NgS2&b=2&j=NDcxODI5NTcS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================